In today’s recent session, 0.55 million shares of the MoonLake Immunotherapeutics (NASDAQ:MLTX) have been traded, and its beta is 1.26. Most recently the company’s share price was $46.45, and it changed around -$3.4 or -6.82% from the last close, which brings the market valuation of the company to $2.92B. MLTX at last check was trading at a discount to its 52-week high of $64.98, offering almost -39.89% off that amount. The share price’s 52-week low was $35.11, which indicates that the recent value has risen by an impressive 24.41% since then. We note from MoonLake Immunotherapeutics’s average daily trading volume that its 10-day average is 0.53 million shares, with the 3-month average coming to 348.98K.
MoonLake Immunotherapeutics stock received a consensus recommendation rating of Overweight, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 17 analysts rate the stock as a Sell; another 9 rate it as Overweight. Among the rest, 3 recommended MLTX as a Hold, whereas 5 deemed it a Buy, and 0 rated it as Underweight. MoonLake Immunotherapeutics is expected to report earnings per share of -0.44 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MoonLake Immunotherapeutics (NASDAQ:MLTX) trade information
Instantly MLTX has been showing red trend so far today with a performance of -6.82% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 56.00 on recent trading dayincreased the stock’s daily price by 17.05%. The company’s shares are currently down -23.08% year-to-date, but still down -10.36% over the last five days. On the other hand, MoonLake Immunotherapeutics (NASDAQ:MLTX) is -0.32% down in the 30-day period. We can see from the shorts that 7.77 million shares have been sold at a short interest cover period of 36.73 day(s).
The consensus price target as assigned by Wall Street analysts is $76, which translates to bulls needing to increase their stock price by 38.88% from its current value. Analyst projections state that MLTX is forecast to be at a low of $62 and a high of $100.
MoonLake Immunotherapeutics (MLTX) estimates and forecasts
MoonLake Immunotherapeutics share prices are performing particularly well not compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 0.59 percent over the past six months and at a -110.96% annual growth rate that is well below the industry average of 17.70%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will loss -144.40% in revenue this quarter, and will report a decrease of -316.70% in the next quarter.
MLTX Dividends
MoonLake Immunotherapeutics’s next quarterly earnings report is expected to be released on 2024-Nov-12.
MoonLake Immunotherapeutics (NASDAQ:MLTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.27% of MoonLake Immunotherapeutics shares, and 99.33% of them are in the hands of institutional investors. The stock currently has a share float of 117.23%. MoonLake Immunotherapeutics stock is held by 168.0 institutions, with BVF INC/IL being the largest institutional investor. By 2024-06-30, it held 34.7258% of the shares, which is about 21.75 million shares worth $956.4 million.
CORMORANT ASSET MANAGEMENT, LP, with 13.5609% or 8.49 million shares worth $373.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
